1
|
Shafiq I, Isse S, Khan N, Uzebeck M, Zoumot Z, Shabeer S, Wahla A. A retrospective, descriptive analysis identifying non‑small cell lung cancer molecular markers. Mol Clin Oncol 2024; 20:41. [PMID: 38756870 PMCID: PMC11097133 DOI: 10.3892/mco.2024.2738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Accepted: 03/27/2024] [Indexed: 05/18/2024] Open
Abstract
Non-small-cell lung cancer (NSCLC) remains one of the leading causes of cancer mortality worldwide. The aim of the present study was to review the histologic patterns and molecular drivers of NSCLC in patients with lung cancer. The electronic health records (EHR) of all patients diagnosed with lung cancer between April 2015 and September 2022 were obtained from a tertiary care hospital and retrospectively analysed. A total of 224 patients were identified of which 192 (138 males and 54 females) were included in the final analysis. Adenocarcinoma was the most common type of lung cancer identified, and accounted for 134 patients (70%), followed by squamous cell carcinoma in 47 (24%) patients, while large cell lung cancer was noted in only 5 (3%) patients. The most common mutations were EGFR mutations and were detected in 29 (15%) patients, followed by PD-L1 expression which was present in 56 (24.7%) patients, KRAS in 16 (8.3%) patients, ALK1 in 8 (4.2%) patients and BRAF, ROS1 and MET were present in 3 (1.6%), 2 (1%) and 1 (0.5%), respectively. The findings from the present study offer important insights into the epidemiological, clinical and molecular characteristics of NSCLC. Further research is warranted to explore the clinical implications of these findings.
Collapse
Affiliation(s)
- Irfan Shafiq
- Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates
| | - Said Isse
- Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates
| | - Naureen Khan
- Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates
| | - Mateen Uzebeck
- Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates
| | - Zaid Zoumot
- Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates
| | - Safia Shabeer
- Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates
| | - Ali Wahla
- Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates
| |
Collapse
|
2
|
Souilamas RM, Uzbeck MH, Bayrak Y, Guenif N, Hamed F, Shafiq I, Kakar V, Elkaissi M, Abada H, Younes F, Alzaabi A, Zoumot Z, Wahla A. Thoracic surgery in United Arab Emirates. J Thorac Dis 2022; 14:788-793. [PMID: 35399238 PMCID: PMC8987826 DOI: 10.21037/jtd-21-1109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Accepted: 11/05/2021] [Indexed: 11/16/2022]
Abstract
The United Arab Emirates (UAE) has undergone a significant change in its population and economy in the last decades and in parallel its healthcare system has evolved rapidly to provide advanced, innovative and world-leading care. At the forefront of this revolution in healthcare is the development of a multidisciplinary multimodality thoracic service provision, offered at quaternary referral hospitals amalgamating academics, training, research and innovation. Previously, thoracic service care was limited to single providers at various public and private hospitals, usually performing lower complexity cases. Most complex thoracic cases were repatriated outside the UAE. This practice was replaced with the opening of Cleveland Clinic Abu Dhabi (CCAD), in 2015, which created a multidisciplinary thoracic program. This included the start of a mini-invasive surgical and lung transplantation program. Since that time other public and private hospitals have emerged providing care in a similar model. The impact of these programs has been a decreased transfer of patients abroad for treatment. Under the umbrella of the Emirates Thoracic Society (ETS) a platform for greater collaboration aimed at improving patient care, potential research and physician education has been created. Direct links have been established with world-leading Thoracic surgery and Respiratory Medicine Centers facilitating this development and offering support and guidance. This article charts these changes in thoracic care in the recent past, present, and delineates plans for the future in the UAE.
Collapse
Affiliation(s)
- Redha Mohammed Souilamas
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Mateen Haider Uzbeck
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Yusuf Bayrak
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Nacira Guenif
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Fadi Hamed
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Irfan Shafiq
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Vivek Kakar
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Mahmoud Elkaissi
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Hicham Abada
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Fadi Younes
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Ashraf Alzaabi
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Zaid Zoumot
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Ali Wahla
- Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| |
Collapse
|
3
|
Abuzakouk M, Saleh K, Algora M, Nusair A, Alameri J, Alshehhi F, Alkhaja S, Badr M, Abdallah K, De Oliveira B, Nadeem A, Varghese Y, Munde D, Salam S, Abduljawad B, Elkambergy H, Wahla A, Taha A, Dibu J, Bayrlee A, Hamed F, AbdelWareth L, Rahman N, Guzman J, Mallat J. Convalescent Plasma Efficacy in Life-Threatening COVID-19 Patients Admitted to the ICU: A Retrospective Cohort Study. J Clin Med 2021; 10:2113. [PMID: 34068847 PMCID: PMC8153619 DOI: 10.3390/jcm10102113] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 05/07/2021] [Accepted: 05/11/2021] [Indexed: 12/15/2022] Open
Abstract
(1) Background: There are limited data regarding the efficacy of convalescent plasma (CP) in critically ill patients admitted to the intensive care unit (ICU) due to coronavirus disease 2019 (COVID-19). We aimed to determine whether CP is associated with better clinical outcome among these patients. (2) Methods: A retrospective single-center study including adult patients with laboratory-confirmed SARS-CoV-2 infection admitted to the ICU for acute respiratory failure. The primary outcome was time to clinical improvement, within 28 days, defined as patient discharged alive or reduction of 2 points on a 6-point disease severity scale. (3) Results: Overall, 110 COVID-19 patients were admitted. Thirty-two patients (29%) received CP; among them, 62.5% received at least one CP with high neutralizing antibody titers (≥1:160). Clinical improvement occurred within 28 days in 14 patients (43.7%) of the CP group vs. 48 patients (61.5%) in the non-CP group (hazard ratio (HR): 0.75 (95% CI: 0.41-1.37), p = 0.35). After adjusting for potential confounding factors, CP was not independently associated with time to clinical improvement (HR: 0.53 (95% CI: 0.23-1.22), p = 0.14). Additionally, the average treatment effects of CP, calculated using the inverse probability weights (IPW), was not associated with the primary outcome (-0.14 days (95% CI: -3.19-2.91 days), p = 0.93). Hospital mortality did not differ between CP and non-CP groups (31.2% vs. 19.2%, p = 0.17, respectively). Comparing CP with high neutralizing antibody titers to the other group yielded the same findings. (4) Conclusions: In this study of life-threatening COVID-19 patients, CP was not associated with time to clinical improvement within 28 days, or hospital mortality.
Collapse
Affiliation(s)
- Mohamed Abuzakouk
- Division of Rheumatology, Department of Internal Medicine, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates
- Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA; (M.A.); (A.W.)
| | - Khaled Saleh
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Manuel Algora
- Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA; (M.A.); (A.W.)
- Pathology and Laboratory Medicine Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates;
| | - Ahmad Nusair
- Medical Subspecialties Institute-Infectious Diseases, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates;
| | - Jawahir Alameri
- Education Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (J.A.); (F.A.); (S.A.)
| | - Fatema Alshehhi
- Education Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (J.A.); (F.A.); (S.A.)
| | - Sara Alkhaja
- Education Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (J.A.); (F.A.); (S.A.)
| | - Mohamed Badr
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Khaled Abdallah
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Bruno De Oliveira
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Ashraf Nadeem
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Yeldho Varghese
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Dnyaseshwar Munde
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Shameen Salam
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Baraa Abduljawad
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Hussam Elkambergy
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Ali Wahla
- Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA; (M.A.); (A.W.)
| | - Ahmed Taha
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Jamil Dibu
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Ahmed Bayrlee
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Fadi Hamed
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Laila AbdelWareth
- Pathology and Laboratory Medicine Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates;
| | - Nadeem Rahman
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Jorge Guzman
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
| | - Jihad Mallat
- Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA; (M.A.); (A.W.)
- Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates; (K.S.); (M.B.); (K.A.); (B.D.O.); (A.N.); (Y.V.); (D.M.); (S.S.); (B.A.); (H.E.); (A.T.); (J.D.); (A.B.); (F.H.); (N.R.); (J.G.)
- Faculty of Medicine, Normandy University, UNICAEN, ED 497, 1400 Caen, France
| |
Collapse
|
4
|
AlNuaimi D, ElKaissi M, Wahla A, Shafiq I, Abdulghaffar S. Metastatic pulmonary calcifications postcardiac transplant in a 15-year-old patient: A case report and review of literature. Radiol Case Rep 2020; 15:1978-1982. [PMID: 32874395 PMCID: PMC7452014 DOI: 10.1016/j.radcr.2020.07.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2020] [Revised: 07/22/2020] [Accepted: 07/24/2020] [Indexed: 11/20/2022] Open
Abstract
Metastatic pulmonary calcification is a metabolic lung disease that occurs due to a prolonged hypercalcemic state where calcium salts precipitate into numerous foci or nodules of fluffy calcifications in the lung apices, usually bilaterally. Calcifications can also occur in other organs such as in the stomach and the kidneys. It is often underdiagnosed and is usually associated with end stage renal failure and resultant secondary hyperparathyroidism. Nevertheless, it is rarely reported in the postcardiac surgery status and cardiac transplant patients. We present a case of a 15-year-old male patient with a recent history of cardiac transplant due to a complex congenital heart disease where findings of extensive metastatic pulmonary calcifications were seen a routine follow-up chest radiograph. Clinical manifestations of metastatic pulmonary calcifications can range from having no symptoms or mild dyspnea on exertion to fulminant respiratory failure. Therefore, early recognition of imaging features and initiation of proper management is crucial to the patient's outcome.
Collapse
Affiliation(s)
- Dana AlNuaimi
- Cleveland Clinic Abu Dhabi, AlMaryah Island, Abu Dhabi, United Arab Emirates
| | - Mahmoud ElKaissi
- Cleveland Clinic Abu Dhabi, AlMaryah Island, Abu Dhabi, United Arab Emirates
| | - Ali Wahla
- Cleveland Clinic Abu Dhabi, AlMaryah Island, Abu Dhabi, United Arab Emirates
| | - Irfan Shafiq
- Cleveland Clinic Abu Dhabi, AlMaryah Island, Abu Dhabi, United Arab Emirates
| | | |
Collapse
|